Anti-tumour activity of bisphosphonates in human myeloma cells.
Multiple myeloma is a haematological malignancy characterized by an expansion of malignant plasma cells within the bone marrow and is frequently associated with bone disease involving the development of osteolytic bone lesions, pathological fractures, osteoporosis and hypercalcaemia. A class of anti-resorptive drugs known as bisphosphonates have been in use to treat osteoclast-mediated bone diseases for the past 3 decades, and are currently proving effective in the treatment of the bone disease associated with multiple myeloma. Recent studies have suggested that bisphosphonate treatment may also result in an improvement in survival in some patients with multiple myeloma. These effects on survival may reflect an indirect effect of the bisphosphonates on tumour growth, via inhibition of osteoclast activity and hence a reduction in the release of tumour growth factors. However, it is also possible that bisphosphonates may have a direct effect on myeloma cells. In support of this we have demonstrated that bisphosphonates can decrease cell proliferation and induce apoptosis in human myeloma cells in vitro, and this review discusses the possibility that bisphosphonates may have not only an anti-resorptive action, but may also have a direct anti-tumour activity.
Department of Medicine and Therapeutics, University of Aberdeen Medical School, UK.
C M
CM
Shipman
M J
MJ
Rogers
J F
JF
Apperley
R
R
Graham
G
G
Russell
P I
PI
Croucher
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis; D001847:Bone Diseases / Q000188:drug therapy / Q000209:etiology; D002452:Cell Count / Q000187:drug effects; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D013534:Survival; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D004164:Diphosphonates